Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

NCC Group H1 revenues fall

(Sharecast News) - Cybersecurity firm NCC Group said on Thursday that revenues had fallen in the six months ended 31 March amid a decline in its "high-volume, lower value testing and compliance engagements". NCC said overall revenue was down 6% at £156.8m, with cybersecurity revenues dropping 7.8% to £123.5m and Escode revenues growing 1.2% to £33.3m as the unit delivered a tenth consecutive quarter of year-on-year growth. Gross margins improved slightly, up from 42.8% to 43.2%

As a result, adjusted underlying earnings slumped 15.7% to £21.5m, even as pre-tax profits surged 97.6% to £16.6m due to NCC's sale of its Fox Crypto business for £65.6m in March. Operating profits were also higher, up 70.9% at £20.0m.

The FTSE 250-listed firm noted that FY25 adjusted EBITDA remains in line with previous guidance as it looks to maintain gross margins and realise operational efficiencies.

NCC also noted that it was currently investigating options for its Escode business, including a potential sale, and was now holding discussions with interested parties.

Chief executive Mike Maddison said: "Demand for cyber security services has never been clearer, reflected in strong pipeline growth, particularly in solutions related to our investment areas.

"We are making progress reflecting the changing market and pivoting to strategic client relationships and projects underpinned by recurring revenue, multidisciplinary capabilities and global delivery."

As of 0855 BST, NCC shares were down 9.37% at 149.54p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.